Sarco-COVID Study: Measuring the Loss of Skeletal Muscle Mass in the Hospitalized Patient With the Diagnosis of COVID-19 (SARCO-COVID)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04780126|
Recruitment Status : Recruiting
First Posted : March 3, 2021
Last Update Posted : March 3, 2021
The COVID-19 pandemic is having a devastating global impact, and older adults who experience it are at higher risk of death from the disease. However, survivors of the disease have a greater risk of suffering from pathologies such as sarcopenia, which is more frequent in younger adults and with greater severity of the disease.
Sarcopenia is present in 5-13% of people between 60 and 70 years old and in 11-50% of the population over 80 years of age. The diagnosis of sarcopenia has advanced in recent years by establishing homogeneous criteria in different consensuses that necessarily combine two elements: generalized loss of strength accompanied by loss of skeletal muscle mass. Today there are three consensuses for the diagnosis of sarcopenia: the international (IWGS), the European (EWGSOP), and the most recent from a US cohort (FNIH). In all of them, the measurement of skeletal muscle mass constitutes one of the two diagnostic criteria.
The main methods to measure this muscle loss that are established are imaging techniques (computerized tomography (CT), magnetic resonance imaging (MRI), dual-energy X-ray absorptiometry (DEXA) and ultrasound.
The most common ultrasound measurements used for this purpose are the muscle thickness (cm) at the point of the ultrasound path of maximum muscle thickness, the cross-sectional area (area calculated by the basic software at the point of maximum muscle thickness), and the pennation angle (angle formed between deep muscle fascia and muscle fibers). The first two measurements can be made on several long muscles, while the pennation angle is usually made primarily on the medial gastrocnemius (internal twin) muscle. They are easy to obtain, bloodless, and reproducible measurements.
Research efforts at this point in the pandemic should focus on the longer-term consequences of the disease, sequelae such as sarcopenia in patients who have suffered from COVID-19. At the same time, clinicians must become increasingly aware of the condition and its measurement integrated into clinical practice. The knowledge provided by studies such as the one presented will allow the development of specific interventions.
The risk of sarcopenia should be considered when carrying out a risk / benefit assessment of the established treatment (for example, dexamethasone), and considering a multidisciplinary treatment that includes dietary inputs.
|Condition or disease||Intervention/treatment|
|Sarcopenia Covid19||Other: Sarcopenia diagnosis|
|Study Type :||Observational [Patient Registry]|
|Estimated Enrollment :||64 participants|
|Observational Model:||Ecologic or Community|
|Target Follow-Up Duration:||1 Month|
|Official Title:||Measuring the Loss of Skeletal Muscle Mass in the Hospitalized Patient With the Diagnosis of COVID-19|
|Actual Study Start Date :||February 26, 2021|
|Estimated Primary Completion Date :||April 30, 2021|
|Estimated Study Completion Date :||May 31, 2021|
COVID-19 pneumonia patients
Patients over 18 years of age who are admitted to the hospital and whose main diagnosis and reason for staying is COVID-19 pneumonia will be included.
Other: Sarcopenia diagnosis
History, physical, laboratory and ultrasound parameters to diagnose sarcopenia
- Loss of muscle mass [ Time Frame: 1 month ]Quantify the loss of muscle mass in hospitalized patients in areas of Internal Medicine with a diagnosis of COVID-19
- Prevalence of sarcopenia [ Time Frame: 1 month ]Analyze the clinical characteristics and the prevalence of sarcopenia in the patients included in the study.
- Normal values of muscle ultrasound thickness [ Time Frame: 1 month ]Analyze the thickness of the rectus femoris, vastus medialis, vastus lateralis, medial gastrocnemius in all patients.
- C reactive protein (CRP) correlated to the presence of sarcopenia [ Time Frame: 1 month ]Analyze the correlation between CRP and the presence of sarcopenia
- Therapy with corticosteroids impact on muscle thickness [ Time Frame: 1 month ]Determine the correlation between muscle thickness and the corticotherapy received (dexamethasone, methylprednisolone, prednisone)
- Normal values of medial gastrocnemius pennation angle in all patients [ Time Frame: 1 month ]Measure medial gastrocnemius pennation angle in all patients
- Ferritin correlated to the presence of sarcopenia [ Time Frame: 1 month ]Analyze the correlation between Ferritin and the presence of sarcopenia
- Fibrinogen correlated to the presence of sarcopenia [ Time Frame: 1 month ]Analyze the correlation between Fibrinogen and the presence of sarcopenia
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04780126
|Contact: Yale Tung Chen, MD PhDemail@example.com|
|Hospital de Emergencias Isabel Zendal||Recruiting|
|Madrid, Spain, 28046|
|Contact: Yale Tung Chen, MD|
|Principal Investigator:||Yale Tung Chen, MD PhD||Hospital Universitario Puerta de Hierro|